To determine whether pHASED could identify a treatment regimen to act as a salvage strategy for sorafenib resistant AML, significant changes in phosphorylation in FLT3-ITD/D835 double mutant cells were compared to FLT3-ITD cell lines (log2 ± 0.5) and each FLT3-ITD/D835 individual dataset analyzed using KSEA. This evidence concerns the gene FLT3 and acute myeloid leukemia.